

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia

Batch 32

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Attendees at the scoping workshop advised that people unable to receive fludarabine are likely to be older than the overall population of people with chronic lymphocytic leukaemia. Attendees also noted that people unable to receive fludarabine are more likely to have a disability due to comorbidities than the overall population of people with chronic lymphocytic leukaemia. Attendees observed that, if it is clinically effective, obinutuzumab may have a positive impact on older people and people with disabilities who have chronic lymphocytic leukaemia.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Technology appraisal recommendations apply to all eligible patients within the marketing authorisation, regardless of likelihood of older age or disability. This is therefore not an equality issue according to the UK legislation that requires special consideration by the technology appraisal Committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): ...Frances Sutcliffe

Date: 20 03 2014